Filing Details

Accession Number:
0000905718-21-001094
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-08-17 12:38:51
Reporting Period:
2021-08-16
Accepted Time:
2021-08-17 12:38:51
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1853816 Dermata Therapeutics Inc. DRMA Pharmaceutical Preparations (2834) DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1279191 T Gerald Proehl 3525 Del Mar Heights Rd., #332
San Diego CA 92130
President, Ceo And Chairman Yes Yes Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-08-16 10,000 $4.96 10,000 No 4 P Indirect By Proehl Family Trust
Common Stock Acquisiton 2021-08-17 17,857 $0.00 17,857 No 4 C Indirect By Allison Taylor Proehl 2020 Irrevocable Trust
Common Stock Acquisiton 2021-08-17 8,928 $0.00 8,928 No 4 C Indirect By Meghan Proehl Wilder 2020 Irrevocable Trust
Common Stock Acquisiton 2021-08-17 35,767 $0.00 35,767 No 4 C Indirect By Sean Michael Proehl 2020 Irrevocable Trust Dated December 18, 2020
Common Stock Acquisiton 2021-08-17 361,147 $0.00 1,278,464 No 4 C Indirect By Proehl Investment Ventures LLC
Common Stock Acquisiton 2021-08-17 111,951 $0.00 1,390,415 No 4 C Indirect By Proehl Investment Ventures LLC
Common Stock Acquisiton 2021-08-17 181,585 $0.00 1,572,000 No 4 C Indirect By Proehl Investment Ventures LLC
Common Stock Acquisiton 2021-08-17 1,247,904 $0.00 2,819,904 No 4 C Indirect By Proehl Investment Ventures LLC
Common Stock Acquisiton 2021-08-17 85,640 $0.00 2,905,544 No 4 C Indirect By Proehl Investment Ventures LLC
Common Stock Acquisiton 2021-08-17 142,857 $0.00 152,857 No 4 P Indirect By Proehl Family Trust
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Proehl Family Trust
No 4 C Indirect By Allison Taylor Proehl 2020 Irrevocable Trust
No 4 C Indirect By Meghan Proehl Wilder 2020 Irrevocable Trust
No 4 C Indirect By Sean Michael Proehl 2020 Irrevocable Trust Dated December 18, 2020
No 4 C Indirect By Proehl Investment Ventures LLC
No 4 C Indirect By Proehl Investment Ventures LLC
No 4 C Indirect By Proehl Investment Ventures LLC
No 4 C Indirect By Proehl Investment Ventures LLC
No 4 C Indirect By Proehl Investment Ventures LLC
No 4 P Indirect By Proehl Family Trust
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series 1d Preferred Stock Disposition 2021-08-17 120,481 $0.00 17,857 $0.00
Common Stock Series 1d Preferred Stock Disposition 2021-08-17 60,240 $0.00 8,928 $0.00
Common Stock Series 1d Preferred Stock Disposition 2021-08-17 241,325 $0.00 35,767 $0.00
Common Stock Series 1d Preferred Stock Disposition 2021-08-17 2,436,657 $0.00 361,147 $0.00
Common Stock Series 1a Preferred Stock Disposition 2021-08-17 2,295,000 $0.00 111,951 $0.00
Common Stock Series 1b Preferred Stock Disposition 2021-08-17 3,722,500 $0.00 181,585 $0.00
Common Stock Series 1c Preferred Stock Disposition 2021-08-17 25,582,050 $0.00 1,247,904 $0.00
Common Stock Series 1 Preferred Stock Disposition 2021-08-17 1,755,622 $0.00 85,640 $0.00
Common Stock Series 1a Warrants Disposition 2021-08-17 573,750 $0.00 27,987 $0.00
Common Stock Warrant to Purchase Common Stock Acquisiton 2021-08-17 27,987 $0.00 27,987 $20.50
Common Stock Warrant to Purchase Common Stock Acquisiton 2021-08-17 142,857 $0.00 142,857 $7.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 2016-11-15 2026-03-14 No 4 C Indirect
27,987 2016-11-15 2026-03-14 No 4 C Indirect
142,857 2021-08-17 2026-08-17 No 4 P Indirect
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 39,512 Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.84 to $5.00 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
  2. The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the "IPO"). The Series 1d Preferred Stock was convertible at any time and had no expiration date.
  3. The Series 1a Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1a Preferred Stock was convertible at any time and had no expiration date.
  4. The Series 1b Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1b Preferred Stock was convertible at any time and had no expiration date.
  5. The Series 1c Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1c Preferred Stock was convertible at any time and had no expiration date.
  6. The Series 1 Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1 Preferred Stock was convertible at any time and had no expiration date.
  7. The Series 1a Preferred Warrants converted into warrants to purchase Common Stock in connection with the IPO.
  8. Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
  9. Reporting Person purchased 142,857 Units in the IPO at $7.00 per Unit Each Unit consists of one share of Common Stock and one warrant to purchase one share of Common Stock.